Bionutrics buys Kirk
This article was originally published in The Tan Sheet
Executive Summary
Phoenix-based supplement and product development firm purchases OTC and generic drug manufacturer Kirk Pharmaceuticals and affiliate Andapharm for $12 mil. in cash and debt, Bionutrics announces July 25. Bionutrics CEO Ronald Lane says the acquisition adds Kirk's "manufacturing and development resources for new OTC drugs employing Bionutrics' proprietary drug technology." Bionutrics is shifting its primary focus from dietary supplement evolvE toward conducting clinical trials for new proprietary supplements "developed to address lipid metabolism and assist in the maintenance of normal cholesterol" slated for launch later this later, according to a June SEC filing...
You may also be interested in...
OTC omeprazole
Synovics Pharmaceuticals announces March 15 it has entered into a binding letter of intent for exclusive, worldwide rights to the development and commercialization of an OTC omeprazole. Contract processor Fluid Air will deliver the product to Phoenix-based Synovics' subsidiary Kirk Pharmaceuticals. Fluid Air's DuraGran technology will allow Synovics to avoid patent infringement, the firm says. Synovics, formerly known as Bionutrics, bought Kirk in July 2005 (1"The Tan Sheet," Aug. 1, 2005, In Brief). Synovics plans to submit an ANDA in the second half of 2007. Perrigo said in a February analyst call it expects to launch an omeprazole product in November 2008 (2"The Tan Sheet," Feb. 5, 2007, p. 5). Under a licensing agreement, Schering-Plough hopes to bring Santarus' immediate release omeprazole product Zegerid to the market as well (3"The Tan Sheet" Nov. 27, 2006, In Brief)...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.